30.3 C
Vientiane
Wednesday, July 9, 2025
spot_img
Home Blog Page 600

Eoptolink Unveils Industry-First 800G Optical Transceiver for Multicore Fiber at OFC 2025

SAN FRANCISCO, March 31, 2025 /PRNewswire/ — Eoptolink Technology Inc., Ltd. (SZSE: 300502), a leading innovator and provider of advanced optical transceiver solutions, is demonstrating industry’s first 800G optical transceiver supporting Multicore Fiber (MCF) at OFC 2025.

The exponential growth of AI workloads is driving an unprecedented demand for bandwidth within data centers necessitates deploying vast amounts of fiber optics cables, creating significant operational challenges such as increased complexity in cable management, higher installation and maintenance costs. Multicore fiber (MCF) refers to an optical fiber that contains multiple light guiding cores within a single strand of optical fiber. Thus, reducing the total fiber count and saving the installation space.

Unlike existing solutions that require external single-core-to-multicore converters, Eoptolink’s innovative 800G transceiver connects directly to MCF. Thus, significantly eases MCF deployment in the datacenter.

“Eoptolink continues to lead the way in optical transceiver innovation, delivering solutions that tackle key industry challenges,”, explains Supriyo Dey, VP of Business Development, Eoptolink Technology Inc., Ltd. “We sincerely thank Sumitomo Electric for providing MCF and related connectivity, which have enabled us to develop this groundbreaking transceiver.

We will be showing live demonstrations of a 1.6T, 800G, LPO, LRO and MCF optical transceiver solutions, at Eoptolink’s booth #2943 at OFC 2025, San Francisco, CA. We welcome you to visit us.

About Eoptolink

Eoptolink Technology Inc., Ltd. (SZSE: 300502) is a leading innovator and provider of advanced optical transceiver solutions for data center, enterprise and telecom networks. Eoptolink is dedicated to research, develop, manufacture and markets a diverse portfolio of high-performance optical transceivers for AI, Cloud Data Center, 4G/5G wireless, Transport & Datacom and FTTX applications all over the world.

Contact Us

USA: 3191 Laurelview Court, Fremont, CA 94538
Thailand: 390/21 Moo 2, Khao Khan Song, Sriracha, Chonburi 20110
China(HQ): No.510 Wulian Avenue, Chengdu 610200
E-mail: sales@eoptolink.com

JarnisTech’s Chongqing Smart Factory Goes Live: AOI Technology Boosts PCB Inspection Efficiency by 600%

SHENZHEN, China, March 31, 2025 /PRNewswire/ — Against the industrial backdrop of surging demand for 5G-A and AI servers, high-end PCB manufacturer JarnisTech announced the official put into production of its Chongqing smart factory. The factory redefines the standard for intelligent manufacturing of high-precision electronic components through an advanced AOI in-line scanning system that increases board quality inspection efficiency to six times that of traditional manual inspection.

JarnisTech's Smart Factory
JarnisTech’s Smart Factory

The smart automated factory is equipped with 25-micron resolution 2D camera systems capable of analyzing 1,800 boards hourly per unit – each requiring only one operator. The proprietary AOI technology examines 2,000+ detection points per board within 0.2 seconds, enabling 99.98% yield rates for complex 72-layer backplanes and slashing average delivery cycles to 72 hours.

“Where traditional PCB plants struggle with labor-intensive quality checks, our closed-loop automation ensures military-grade precision at commercial production speeds,” said Xu, Production Director at JarnisTech. The facility’s 18 international certifications including IPC Class 3 and IATF16949 have secured its position in multiple Fortune 500 tech vendors’ approved supplier lists.

The factory’s dedicated R&D center is accelerating innovation in specialty circuit boards, including cutting-edge products like 100Gbps transmission backplanes and aerospace-grade circuits capable of withstanding 300°C extremes. Its fully-equipped laboratory features advanced testing instruments including ROHS analyzers, enabling 90% of inspection items to be completed within four hours – providing rapid verification support for emerging applications such as medical stretchable flexible circuits.

With 68% fewer personnel than conventional PCB factories, the 300-employee plant delivers $214 million annual output while maintaining 48-hour rush order capabilities.

“This isn’t just scaling production, but reengineering value chains,” emphasized JarnisTech’s CTO. “We transform PCB procurement from cost centers into technical differentiators – clients report 12-15% margin improvements through our engineered solutions.”

About JarnisTech
JarnisTech is a leading high-end specialty PCB manufacturer in China, specializing in high multilayer PCBs, high frequency/high speed PCBs such as Rogers RO4835™, Isola I-Tera® MT40, Taconic RF-35A2™, and others. With precision capabilities such as 22-layer HDI and ±5% impedance control, the company provides complete PCB solutions for high-end electronics industries such as automotive radar, 5G base station AAU, aerospace and medical electronics.

Contact for the press
Cyndi Xiong
Marketing manager
JarnisTech
Phone: +86 135 3094 7255
Email: sales@jarnistech.com 

Learn more at www.jarnistech.com

 

Luye Pharma’s Rivastigmine Twice Weekly Transdermal Patch Approved for Marketing in Japan for the Treatment of Alzheimer’s Dementia

TOKYO, March 31, 2025 /PRNewswire/ — Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japanese Ministry of Health, Labour and Welfare as a new drug, indicated for suppression of progression of dementia symptoms in mild to moderate Alzheimer’s disease. The product is to be marketed as Rivaluen® LA Patch 25.92mg/51.84mg. It is the first extended-release Rivastigmine transdermal formulation approved for marketing in the country.

Developed by Luye Pharma on its proprietary platform for transdermal patches, Rivaluen® LA Patch 25.92mg/51.84mg employs an innovative drug delivery system to release the active ingredient, rivastigmine, transdermally twice a week. This approval is based on the positive results of a Phase Ⅲ clinical trial conducted in Japan for patients with Alzheimer’s type dementia which met the primary efficacy endpoint.

Alzheimer’s disease is a neurodegenerative disease that causes a progressive decline in memory and other aspects of cognition. It is the most common type of dementia, accounting for 50%-75% of all cases[1]. According to statistics, there are over 55 million people living with dementia worldwide[2], and that number is over 5 million in Japan. The lifetime risk of dementia in the Japanese elderly population is over 50%, and more than half of all dementia cases are caused by Alzheimer’s disease[3].

One of the early symptoms of Alzheimer’s type dementia is said to be a decline in the ability to manage medication, and the choice of orally disintegrating tablets or patches has been suggested as a way to improve adherence[4]. Rivastigmine Twice Weekly Transdermal Patch requires a lower application frequency than the once-daily Rivastigmine patches generally available on the market, thereby enabling improved medication adherence among patients. Due to its transdermal route of administration, Rivastigmine Twice Weekly Transdermal Patch is convenient for patients who have difficulty swallowing, and may have the potential to lower the incidence of gastrointestinal adverse reactions such as nausea and vomiting when compared with the oral form of the drug.

To expedite the availability of this innovative treatment for Japanese patients, Luye Pharma entered into an agreement with Towa Pharmaceutical Co., Ltd. (Towa) in December 2020, granting the latter an exclusive license for the development and commercialization of Rivastigmine Twice Weekly Transdermal Patch in Japan. Established in 1951, Towa is a prominent pharmaceutical company in Japan with multiple products in the central nervous system therapeutic area in addition to strong commercial capabilities and a robust operational system in the local market. Luye Pharma looks forward to maintaining close collaboration with Towa to deliver high-quality, innovative drugs as well as services and technologies to those in need.

In addition to Japan, Rivastigmine Twice Weekly Transdermal Patch has been approved for marketing in multiple European countries and China. Furthermore, Luye Pharma is also registering the product with local partners in selected countries of Southeast Asia and Latin America.

Product Overview of the Rivastigmine Twice Weekly Transdermal Patch for the Japanese Market

Product name

RIVALUEN® LA Patch 25.92 mg

RIVALUEN® LA Patch 51.84 mg

Nonproprietary name

Rivastigmine

Indication or efficacy

Suppression of progression of dementia symptoms in mild to moderate Alzheimer’s disease

Dosage and administration

In general, for adults, administer 25.92 mg of Rivastigmine as a starting dose. Increase to 51.84 mg as a maintenance dose four weeks later in principle.

Apply the patch to normal healthy skin on the back, upper arm, or chest. In principle, apply a patch for four days at start and replace the patch every three or four days (twice weekly).

About Luye Pharma Group

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 20 drug candidates in China and more than 10 drug candidates in other international markets. Luye Pharma maintains high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems. The company has achieved multiple innovations in new chemical entities and antibodies, and is also actively making strategic developments in the fields of cell therapies and gene therapies.

Luye Pharma is developing a global supply chain of 8 manufacturing sites built up around the world, with GMP quality management and control systems established in line with international standards. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets — China, the U.S., Europe and Japan, as well as in fast growing emerging markets.

[1] https://www.alzint.org/about/dementia-facts-figures/types-of-dementia/alzheimers-disease/. accessed on March 27, 2025.

[2] https://www.who.int/news-room/fact-sheets/detail/dementia. accessed on March 27, 2025.

[3] T. Iwatsubo, Y. Niimi, H. Akiyama. Alzheimer’s Disease Research in Japan: A Short History, Current Status and Future Perspectives toward Prevention. J Prev Alz Dis 2021;4(8):462-464.

[4] “Guidelines for Medical Treatment and Its Safety in the Elderly 2015,” compiled by the Japan Geriatrics Society and the Research Group on the Japan Agency for Medical Research and Development (AMED) Fund and Research on the Safety of Drug Therapy for the Elderly

NYSE Content advisory: Pre-market update + NYSE Texas opens for business with DJT as its first listing

NEW YORK, March 31, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

Pre-market update + NYSE Texas opens for business with DJT as its first listing

Kristen Scholer delivers the pre-market update on March 31st

  • It’s the final trading day of the first quarter with President Donald Trump’s reciprocal tariffs due Wednesday, April 2. 
  • NYSE Texas opens for business as the first securities exchange to be incorporated in the Lone Star State. “This new offering will allow companies to capitalize on the pro-business dynamics in Texas,” NYSE President Lynn Martin said.
  • Trump Media and Technology Group is set to become the first company to trade on NYSE Texas in a dual listing for the firm with ticker symbol DJT.

Click here to learn more about NYSE Texas

Video – https://mma.prnasia.com/media2/2654069/NYSE_March_31_Market_Update.mp4

 

NamiBox and Tencent Cloud Announce Strategic Partnership with Sichuan Education Press to Launch AI-Powered Writing Solution

“AI Writing Companion” Marks Industry-First Integration of AI Technology and Traditional Composition Materials
Projected to Generate Over 5 million USD in Revenue in 2025

SHANGHAI, March 31, 2025 /PRNewswire/ — Jinxin Technology Holding Company (Nasdaq: NAMI), a leading provider of AI-driven digital content and interactive communication technologies, today announced a major strategic partnership between its flagship platform NamiBox, Tencent Cloud, and Sichuan Education Press. Together, the three parties unveiled AI Writing Companion, an innovative product that represents a breakthrough in AI-powered educational publishing.

This collaboration is expected to generate over  5 million USD  in revenue in 2025, driven by nationwide adoption across schools and strong demand for intelligent learning tools. The product is already being integrated into key educational regions, with wide-scale rollout planned through existing distribution networks.

Built on the Huixue AI Cloud platform co-developed by NamiBox and Tencent Cloud, AI Writing Companion transforms traditional paper-based writing workbooks into intelligent, interactive tools that guide students through the entire composition process. It offers personalized writing support, AI-powered feedback, and natural language interaction—creating a virtual tutor experience for K-12 learners.

“Our collaboration with Tencent Cloud and Sichuan Education Press is a milestone in smart education publishing,” said Jin Xu, CEO of Jinxin Technology. “This product is not only a technological achievement but also a real-world application of how AI can enhance core learning experiences for students across China. We are excited about its growth potential and revenue contribution in the coming year.”

Unlike general-purpose writing apps, AI Writing Companion is built around new AI publishing standards developed jointly by the three companies. These include AI tutoring models, evaluation systems, and composition correction protocols—all aimed at delivering high-quality, curriculum-aligned support in Chinese language learning.

This strategic partnership also reflects NamiBox’s broader commitment to advancing AI in education. By combining Tencent Cloud’s technical infrastructure with NamiBox’s expertise in digital education content, the Huixue AI Cloud ecosystem continues to grow—enabling more personalized, scalable, and efficient educational solutions nationwide.

About Jinxin Technology Holding Company

Headquartered in Shanghai, China, Jinxin Technology Holding Company is an innovative provider of digital content and interactive communication services. Through its flagship platform NamiBox, the Company delivers intelligent, engaging, and curriculum-aligned products powered by advanced AI, AR, and digital human technologies.

Jinxin Technology works closely with China’s leading textbook publishers and educational platforms, providing AI-generated digital content for primary and middle school students. Its distribution channels include:

NamiBox, the Company’s flagship learning app
Telecom and broadcast operators
Third-party educational devices

For more information, please visit the Company’s website at https://ir.namibox.com.

Safe Harbor Statements

This press release contains forward-looking statements as defined under the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and assumptions, involve risks and uncertainties, and may differ materially from actual results. For further discussion of these risks and factors, please refer to the Company’s filings with the U.S. Securities and Exchange Commission.

For Investor and Media Inquiries, Please Contact:
Jinxin Technology Holding Company
Investor Relations Department
Email: ir@namibox.com

m-FINANCE and CBCX Markets Form Strategic Partnership to Enhance Liquidity Network

HONG KONG, March 31, 2025 /PRNewswire/ — m-FINANCE Limited (“m-FINANCE”), a wholly owned subsidiary of mF International Limited (Nasdaq: MFI) and a provider of forex and bullion trading solutions in Asia, today announced a new strategic partnership with CBCX Markets Limited (“CBCX”), a multi-asset liquidity provider. This partnership is expected to strengthen m-FINANCE’s liquidity network by granting brokerage clients deeper market access, improved execution, and advanced trading conditions.

The collaboration between m-FINANCE and CBCX is driven by a shared commitment to deliver cutting-edge liquidity solutions tailored for brokers. With CBCX’s institutional-level liquidity, brokers can enjoy enhanced market access with tighter spreads and deeper liquidity, for advanced trading conditions. m-FINANCE anticipates that this optimized execution will leverage deep liquidity pools to enhance efficiency, reducing slippage and minimizing costs for end clients.

With CBCX’s liquidity solutions (cbcx.com) and m-FINANCE’s infrastructure, m-FINANCE anticipates its broker clients will experience rapid execution with minimal latency, as it will provide its customers access to its proprietary feature that it believes will allow brokers to capture advantageous spread when hedging orders and maintaining full STP (straight-through processing, an automated electronic workflow that allows for a seamless processing of transactions) connectivity.

The partnership with CBCX is expected to enable brokers to offer institutional-level trading experiences to their clients, backed by deep liquidity, reduced trading costs, and cutting-edge infrastructure. This also marks another step in m-FINANCE’s ongoing commitment to delivering continuous innovation and world-class trading solutions to clients. With CBCX’s liquidity and m-FINANCE’s advanced trading technology, brokers may access to a more competitive, transparent, and efficient trading environment.

Mr. Chi Weng (Dick) Tam, the Executive Director and Chief Executive Officer of m-Finance, commented, “We are proud to collaborate with CBCX to enhance our liquidity solutions. With over 20 years of experience in the forex and bullion markets, we understand the critical importance of market-leading liquidity in driving execution speed, pricing efficiency, and superior trading performance. We believe that CBCX has built a strong reputation for delivering institutional-level liquidity, and we look forward to working closely with their team to provide our clients with unique trading opportunities.”

Echoing this enthusiasm, Bilaal Adam, a Director of CBCX, reinforced CBCX’s  commitment to delivering advanced liquidity solutions and pursuing market excellence:

“At CBCX Markets, we are dedicated to providing brokers, hedge funds and traders with deep liquidity, customized solutions, and ultra-low latency execution. We believe partnering with m-FINANCE will allow us to extend our expertise to a broader network of brokers, hedge funds, and institutional clients. By integrating m-FINANCE’s cutting-edge technology with CBCX Markets’s deep liquidity pools and customized liquidity offerings, we expect to create a more dynamic and flexible trading environment. Our tailored liquidity solutions enable brokers to benefit from tight spreads, reduced slippage, and a high-performance trading ecosystem. In the future, we look forward to working closely with m-FINANCE to continue driving innovation, transparency, and efficiency in global trading markets.”

About mF International Limited

mF International Limited is a British Virgin Islands holding company with three operating subsidiaries in Hong Kong. The Company’s principal Hong Kong subsidiary, m-FINANCE, is a Hong Kong-based experienced financial trading solution provider principally engaged in the development and provision of financial trading solutions via internet or platform as software as a service, or SaaS. m-FINANCE has approximately 20 years of experience providing real-time mission critical forex, bullion/commodities trading platform solutions, financial value-added services, mobile applications and financial information for brokers and institutional clients in the region. With clients located over mainland China, Hong Kong and Southeast Asia, m-FINANCE provides customers with the mF4 Trading Platform, Trader Pro, Bridge and Plugins, CRM System, ECN System, Liquidity Solutions, Cross-platform “Broker+” Solution, Social Trading Apps and other value-added services. For more information, please visit the Company’s website: https://ir.m-finance.com/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “views,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar words. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:

mF International Limited
Investor Relations Department
Email: ir@m-finance.net

ICR, LLC
Robin Yang
Email: mFInternational.IR@icrinc.com
Phone: (646) 308-1475

SF Holding Delivered Record High 2024 Financial Results

  • Record-high annual revenue: RMB284.4 billion, up 10.1% year-over-year
  • Record-high annual net profit attributable to owners of the company: RMB10.2 billion, up 23.5% year-over-year
  • Delivered total shareholder return of RMB10.7 billion

SHENZHEN, China, March 31, 2025 /PRNewswire/ — S.F. Holding Co., Ltd. (‘SF Holding’ or ‘SF’ or ‘the Company’, 002352.SZ; 06936.HK), the largest integrated logistics service provider in Asia, has announced 2024 financial results, demonstrating strong growth in both revenue and profitability.

The Company has an efficient and reliable logistics network infrastructure rooted in China, radiating Asia, and connecting the world. Focusing on its logistics ecosystem, SF Holding has continued to enhance its portfolio of product and service capabilities to provide customers with domestic and international one-stop integrated logistics services.

Commenting on the Company’s 2024 results, Mr. Alex Ho, SF Holding’s Executive Director and Chief Financial Officer, said: “2024 stands as a defining milestone for SF Holding – crowned by high customer satisfaction, record total revenue and profitability, as well as our successful listing on the Hong Kong Stock Exchange in November 2024. Through disciplined capital allocation and operational excellence, we generated robust operating cash flows, translating into sustainable free cash flow growth.”

2024 Operational Highlights

In 2024, the Company achieved strong growth by focusing on its key strategy, “Unite for Shared Goals, Pioneer with Steadfast Drive.” As part of this strategy, SF Holding strengthened organizational vitality by upgrading incentive systems and granting greater business authority to frontline employees. Additionally, the Company enhanced the role of headquarters in supporting business regions, aligning interests across all levels to foster entrepreneurship throughout the organization.

Domestically, the Company achieved business growth by further penetrating customers’ upstream and downstream supply chain scenarios across multiple industries. Logistics revenue in the high-tech, automotive, and industrial manufacturing sectors all grew by over 20% year-over-year. As a result, the main express logistics business achieved revenue of RMB205.8 billion, representing a year-over-year increase of 7.7%.

Internationally, Asia is the Company’s top priority. SF Holding provides customized integrated end-to-end logistics solutions, delivering both cost-efficiency and premium services to customers, and achieved 0-to-1-to-N breakthroughs in international supply chain projects across countries, industries, and business scenarios. Over 45% of Fortune China 500 companies utilize SF Holding’s international logistics services. In its 2024 international operations, the Company won bids for over 100 overseas supply chain projects. As a result of these initiatives, the supply chain and international business achieved RMB70.5 billion in revenue, representing a 17.5% year-over-year increase, effectively securing the Company’s second growing curve.

Alongside business expansion, the Company has achieved sustained profitability growth through continuous improvements in backbone logistics network efficiency and operational model reforms, which combined have driven cost reductions and efficiency enhancements.

Reaffirming Shareholder Commitment

Since 2024, SF Holding has returned a total of RMB10.7 billion to shareholders through cash dividends and share repurchase programs, demonstrating its strong confidence in sustainable cash flow generation and commitment to creating long-term shareholder value.

Notably, on March 28, the Company proposed a final cash dividend distribution of RMB2.2 billion. Together with interim dividends, SF Holding’s total shareholder returns from dividends for 2024 amounted to RMB4.1 billion, representing an annual dividend payout ratio of 40% – an increase of 5 percentage points year-over-year.

Additionally, prior to its November 2024 listing on the Hong Kong Stock Exchange, SF Holding distributed a special one-off cash dividend of RMB4.8 billion. This brought the Company’s 2024 dividend payout ratio to a record-high 87%.

To demonstrate its commitment to shareholder value, SF Holding has allocated RMB4.8 billion in various share repurchase programs since 2022, including RMB1.8 billion worth of shares that were repurchased since 2024.

2024 Key Financial Results

  • For the fiscal year ended December 31, 2024, SF Holding reported total revenue of RMB284.4 billion, representing a 10.1% year-over-year increase.
  • The profit attributable to owners of the Company in 2024 was RMB10.2 billion, representing a year-over-year increase of 23.5%, and the net profit margin increased to 3.6%.
  • In 2024, net cash generated from operating activities of the Company was RMB32.2 billion, representing an increase of 21.1% compared with the same period in 2023, mainly due to the combined effect of the Company’s profit growth and optimized operating cash flow management. Free cash flow surged 70% to RMB22.3 billion, demonstrating significant improvement in cash generation.
  • In 2024, the Company recorded a parcel volume of 13.3 billion, representing an 11.3% year-over-year increase, or 15.3% year-over-year increase, excluding volumes from Fengwang Express (Fengwang), the Company’s franchise model business disposed in June 2023.
  • SF Holding’s flagship product time-definite express recorded 5.8% revenue growth to RMB122.2 billion. Annual parcel volume for this segment increased 12% year-over-year.
  • The Company’s economy express continued to capitalize on its competitive edge to serve e-commerce customers in the year. The segment’s parcel volume (excluding volumes from Fengwang) increased 18% year-over-year, while its revenue increased by 11.8%.
  • Revenue for the freight segment increased by 13.8% to RMB37.6 billion with significantly improved profitability. The structural cost-saving initiatives enabled competitive pricing strategies, driving over 20% annual growth in shipment volume.
  • SF Holding’s intra-city segment achieved 22.4% revenue growth with net profit surging by 162%.

Business Outlook

Building on its leadership in Asia, SF Holding is rapidly applying its proven expertise to further develop its market presence. By deepening its “The One in Asia” strategy, the Company remains committed to seamlessly connecting Asia and the world with its international logistics and supply chain capabilities.

Looking ahead, as the demand for integrated end-to-end logistics solutions continues to rise, SF Holding aims to become the go-to logistics partner of our business and retail customers in Asia. SF Holding plans to leverage its well-recognized brand, cost advantages, and integrated logistics service capabilities, driving sustainable and healthy growth of business to foster shared success and create enduring value together.

About SF Holding

Founded in 1993, S.F. Holding Co., Ltd. (002352.SZ; 06936.HK) is the largest integrated logistics service provider in Asia and the fourth largest globally. Listed on the Shenzhen Stock Exchange and the Hong Kong Stock Exchange, SF Holding is the constituent stock in the CSI 300 Index and MSCI Emerging Market Index. Demonstrating a commitment to being fast, reliable, and customer-centric, the Company possesses digital technology to promote the development of intelligent and green supply chains.

For further information, please visit https://ir.sf-express.com/en/.    

Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research

Collaboration to apply Lunit’s AI technologies across NCI’s broad spectrum of cancer studies, aiming to accelerate personalized cancer care

SEOUL, South Korea, March 31, 2025 /PRNewswire/ — Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a collaboration with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), to explore innovative applications of AI in cancer research. This collaboration aims to advance research into the tumor microenvironment and immune phenotyping, analyzing NCI data to uncover insights that could drive personalized cancer care.

Lunit and the National Cancer Institute (NCI) join forces to advance AI-powered biomarker research and accelerate personalized cancer care.
Lunit and the National Cancer Institute (NCI) join forces to advance AI-powered biomarker research and accelerate personalized cancer care.

Under the agreement, Lunit tools will be made available to NCI Center for Cancer Research (CCR) investigators, across NCI CCR’s portfolio of clinical trials. Lunit will analyze whole-slide images obtained from NCI’s clinical studies, using Lunit AI-powered biomarker technologies, including Lunit SCOPE® IO and Lunit SCOPE universal IHC. This broad collaboration will enable image-analysis AI to become a core part of cancer research practice.

The two parties plan to jointly prepare publications, presentations, and reports. The primary objective of this partnership is to develop data-driven insights that can help personalize treatment approaches for cancer patients. By applying Lunit’s AI solutions across NCI’s extensive cancer research portfolio, the collaboration seeks to accelerate discoveries that optimize immunotherapy strategies, improve patient outcomes, and pave the way for more targeted cancer care.

“This collaboration with the NCI is a testament to the power and potential of Lunit’s AI-driven solutions in advancing the frontier of cancer research,” said Brandon Suh, CEO of Lunit. “By applying our technologies across NCI’s unparalleled research expertise and clinical data, we aim to uncover meaningful insights that can transform cancer treatment and deliver more personalized care to patients worldwide. We are honored to work with one of the world’s leading cancer research institutions to tackle some of the toughest challenges in oncology.”

About Lunit

Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer through AI. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.